Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day

The company showcased three core programs developed through this platform

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy

Veerhealth Care enters into contract manufacturing agreement

Commercial production is expected to begin soon

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries

Suraksha Diagnostic unveils Eastern India's largest genomics lab

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone